Affinia Therapeutics
Affinia Therapeutics is a pioneering company in gene therapy, focusing on developing innovative adeno-associated virus (AAV) vectors to treat rare and prevalent diseases. Utilizing their proprietary ART (Affinia Rationally-designed Therapies) platform, they leverage AI and structural modeling to enhance the targeting and effectiveness of gene therapies, particularly for heart and nervous system diseases. With a team experienced in drug development and a commitment to patient-centered solutions, Affinia aims to set a new standard in gene therapy, expanding its reach to address significant unmet medical needs.
Affinia Therapeutics
Affinia Therapeutics is a pioneering company in gene therapy, focusing on developing innovative adeno-associated virus (AAV) vectors to treat rare and prevalent diseases. Utilizing their proprietary ART (Affinia Rationally-designed Therapies) platform, they leverage AI and structural modeling to enhance the targeting and effectiveness of gene therapies, particularly for heart and nervous system diseases. With a team experienced in drug development and a commitment to patient-centered solutions, Affinia aims to set a new standard in gene therapy, expanding its reach to address significant unmet medical needs.
